Biotech and pharma companies sit on genuinely compelling science and rarely put it on video, because the format feels harder to get through compliance than a written page. We build a video strategy that clears review and communicates the science to investors, technical buyers, and patients without dumbing it down.
The Problem
Video feels like the riskiest format to get through compliance
A single misspoken claim in a video is harder to correct than a typo on a webpage, so many biotech and pharma teams avoid video entirely rather than deal with the perceived compliance risk. This leaves a channel with some of the best engagement potential in the entire marketing mix almost completely unused, while written content that gets less attention absorbs most of the budget.
Complex science does not translate to a 30-second cut
A mechanism of action, a clinical trial design, or a platform technology cannot be meaningfully explained in the short-form formats most video strategies default to. Teams either oversimplify to the point of losing scientific credibility with technical audiences, or they produce long, dense videos that lose the audience before the key point lands.
One video gets stretched across incompatible audiences
Investors want to understand the commercial thesis and risk profile. Scientific and clinical audiences want mechanism-level detail and data. Patients or caregivers want clarity and honesty about what a treatment does and does not do. A single video built to serve all three usually serves none of them well, and teams rarely have the budget model or production plan to build separate videos for each.
No consistent production pipeline means video happens once a year
Without a repeatable process for scripting, compliance review, and production, video becomes a one-off project tied to a major event like a conference or funding announcement, rather than an ongoing channel. This means the format never builds an audience or a library, and each video starts from zero instead of building on what came before.
How We Help
Assessment starts with an inventory of what scientific and commercial substance already exists – publications, pipeline data, leadership expertise – that could translate to video, and an honest look at how the current compliance review process handles video versus written content. Most teams are surprised to learn the review process itself, not the content, is the real obstacle.
Strategy development separates video into audience-specific tracks, the same way we approach other content formats for biotech and pharma. Investor-facing video covers pipeline milestones and leadership credibility, built around actual news cycles. Scientific and technical video goes deep on mechanism and data, built for platforms and formats where a technical audience will actually sit through longer content. Patient or caregiver video uses a different tone entirely, prioritizing clarity over promotion.
Execution includes building a compliance-friendly scripting and review process specifically for video – pre-cleared claim language built into scripts before filming starts, so the compliance review happens on the script rather than after the final cut, which is far more expensive to revise. We also build a production pipeline that supports ongoing output rather than one-off projects: templated formats for recurring content types like pipeline updates or conference recaps, paired with higher-production video for major milestones.
Measurement tracks video performance by audience segment and by where it sits in the buyer or investor journey, not just view counts. We look at whether investor-facing video correlates with deal interest, whether scientific video drives engagement from the technical community, and adjust the production mix based on what is actually working.
What we deliver
- Compliance-integrated scripting process – claim language pre-cleared before filming, not after the final cut
- Audience-segmented video strategy – distinct approaches for investor, scientific, and patient or caregiver audiences
- Repeatable production pipeline – templated formats for recurring content paired with a plan for major milestone video
- Distribution plan mapped to where each audience actually watches video
The reason biotech and pharma companies avoid video is not the format, it is the review process. Move compliance review to the script stage instead of the final cut, and video stops being the riskiest channel in the mix and becomes one of the most effective.
Our Methodology
Our 90-day video marketing sprint opens with an inventory of existing scientific and commercial substance and an audit of the current compliance review process for video content specifically. This produces a clear picture of what stories are worth telling and where the review bottleneck actually sits.
Days 30 to 60 build the compliance-integrated scripting process alongside legal and regulatory reviewers, along with the audience-segmented strategy and initial script drafts for priority video projects. Days 60 to 90 move into production and initial publishing, along with early measurement of engagement by audience segment.
What makes this different from a standard video marketing engagement is that we solve the compliance problem before we solve the creative problem. A great script is worthless if it takes six weeks to clear review after filming, so we build the review process into the scripting stage from the start.
How We Work
The first 30 days run close with your marketing and legal or regulatory teams to complete the audit and build the compliance-integrated scripting process – typically 2-3 days a week. Days 30 to 90 shift toward production support and initial publishing, usually 1-2 days a week depending on production volume.
You provide access to existing scientific and commercial content, subject matter experts for interviews, and time with your legal or regulatory reviewer during the scripting process build. We handle strategy, scripting, and production coordination – filming and editing can run through our network, your existing vendors, or a hybrid depending on budget and existing relationships.
Weekly working sessions track script development and production scheduling. Monthly reviews cover engagement by audience segment and adjust the production mix. Most engagements run 4-6 months for the initial strategy and pipeline build, with an ongoing retainer for continued production.
- Faster compliance review turnaround on video content
- A working video library segmented by investor, scientific, and patient audiences
- A repeatable production pipeline instead of one-off annual projects
If your biotech & pharma company needs video marketing strategy leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does video marketing strategy cost for a biotech or pharma company?
Strategy and process development typically runs $10K to $20K per month, with production costs scoped separately depending on video complexity and volume. Companies with existing raw scientific content and subject matter experts available for interviews see faster, more cost-effective production than companies starting from a blank slate.
How long before we see results from a video marketing engagement?
The compliance-integrated scripting process and initial script drafts are typically ready within 45-60 days. First videos usually publish by month 3, with engagement data building over the following months as the audience-segmented library grows. Investor and scientific audience engagement compounds as the library expands past a handful of videos.
How does the video marketing team integrate with our existing staff?
We work directly with your marketing team, subject matter experts for interviews and scripting input, and your legal or regulatory reviewer during the scripting process specifically. Your team retains final publishing decisions – we build the strategy, scripts, and production plan, and coordinate execution through our network or yours.
What makes Winston Francois different from a typical video production agency?
Most video agencies focus on production quality and leave compliance review as a problem for after the shoot, which is why so much biotech and pharma video work stalls or gets cut. We build the compliance review into the scripting stage before anything is filmed, and we segment content by audience instead of producing one video meant to serve everyone.
How do you measure ROI from a video marketing investment?
We track engagement by audience segment – investor, scientific, and patient or caregiver – and look at how investor-facing video correlates with deal or funding interest, and how scientific video drives engagement from the technical community. Most engagements need 3-4 months of published content before the pattern is clear.
What type of biotech or pharma company is the right fit for this service?
Companies with genuine scientific or commercial substance to communicate – real pipeline data, real leadership expertise, real clinical results – who have avoided video because of compliance concerns rather than lack of content. The best fit is a company ready to invest in an ongoing production pipeline, not a single one-off video project.
